Literature DB >> 31938298

PD-1, FOXP3, and CSF-1R expression in patients with Hodgkin lymphoma and their prognostic value.

Chaoyu Wang1, Bing Xia1, Tengteng Wang1, Chen Tian1, Yong Yu1, Xiaoxiong Wu2, Baocun Sun3, Wanming Da4, Suxia Li4, Yizhuo Zhang1.   

Abstract

Despite advances in the treatment of Hodgkin lymphoma (HL), there is a need for development of reliable prognostic biomarkers and improved stratification of patients for effective therapeutic intervention. The immune microenvironment is the key to HL pathophysiology. The aim of this study was to identify expression of microenvironment-related biomarkers (PD-1, FOXP3, and CSF-1R) immunohistochemically and determine their association with clinicopathological features and prognosis in HL. We found that a high number of non-HRS cells expressing CSF-1R confers inferior overall survival (OS), which is associated with the presence of Epstein-Barr virus in neoplastic cells (P=0.009). Increased FOXP3 expression confered superior OS and progression-free survival (PFS). PD-1 expression had no significant association with OS and PFS. The combination of FOXP3 and PD-1 or CSF-1R may yield better prognostic stratification. IJCEP
Copyright © 2018.

Entities:  

Keywords:  CSF-1R; FOXP3; Hodgkin lymphoma; PD-1; prognostic

Year:  2018        PMID: 31938298      PMCID: PMC6958205     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  2 in total

1.  M-CSFR expression in the embryonal component of hepatoblastoma and cell-to-cell interaction between macrophages and hepatoblastoma.

Authors:  Lianbo Li; Tomoaki Irie; Daiki Yoshii; Yoshihiro Komohara; Yukio Fujiwara; Shigeyuki Esumi; Masashi Kadohisa; Masaki Honda; Shinya Suzu; Toshiharu Matsuura; Kenichi Kohashi; Yoshinao Oda; Taizo Hibi
Journal:  Med Mol Morphol       Date:  2022-05-21       Impact factor: 2.070

2.  Overexpression of macrophage-colony stimulating factor-1 receptor as a prognostic factor for survival in cancer: A systematic review and meta-analysis.

Authors:  Huaqing Mo; Yanrong Hao; Yanru Lv; Zenan Chen; Jingyi Shen; Shu Zhou; MengJie Yin
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.